Highbridge exits MTNB stake: 13G/A shows 0% beneficial ownership
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Matinas BioPharma (MTNB): ownership update — Highbridge Capital Management, LLC filed Amendment No. 2 to Schedule 13G reporting 0% beneficial ownership of Matinas BioPharma common stock. The filing shows 0 shares beneficially owned with 0 sole or shared voting and dispositive power.
The date of event triggering the filing is 09/30/2025. Highbridge certifies the securities referenced were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Positive
- None.
Negative
- None.
FAQ
What did Highbridge report in its Schedule 13G/A for MTNB?
Highbridge reported 0% beneficial ownership of Matinas BioPharma common stock, with 0 shares beneficially owned.
Who is the reporting person in this MTNB 13G/A?
The reporting person is Highbridge Capital Management, LLC, a Delaware limited liability company.
What is the event date associated with this MTNB filing?
The filing lists the date of event as 09/30/2025.
How much voting power did Highbridge report for MTNB?
Highbridge reported 0 sole voting power and 0 shared voting power.
What class of securities does the MTNB filing cover?
Common Stock, par value $0.0001 per share, CUSIP 576810303.
What certification did Highbridge include in the MTNB 13G/A?
It certified holdings are in the ordinary course of business and not for changing or influencing control.